Among patients with laboratory-confirmed influenza, does treatment with oseltamivir reduce morbidity and mortality?
Metadata[+] Show full item record
Among patients with laboratory-confirmed influenza, does treatment with oseltamivir reduce morbidity and mortality? EVIDENCE-BASED ANSWER: Yes, in the hospital. Treatment with neuraminidase inhibitors (NAI), most commonly oseltamivir, is associated with improved survival in hospitalized patients. Survival is higher when NAI treatment is started within 5 days of illness (SOR: B, retrospective cohort). For outpatient adults, oseltamivir reduces the duration of symptoms with uncomplicated influenza by about 1 day, even when treatment is started 48 hours or more after illness onset. Oseltamivir reduces the risk of lower respiratory tract complications and admittance to hospital (SOR: A, meta-analysis of RCTs).
Evidence-based practice 20, no. 1 (2017): 09